Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology · 2026
Sociodemographic Disparities in First-Line Treatment and Outcome Patterns in Women with HR+/HER2- Metastatic Breast Cancer.
СтатьяНаблюдательное исследованиеНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Vidal Gregory A, Katz Julie, Sadetsky Natalia, Dabrowski Elizabeth C, Kaufman Peter A, Verret Wendy, Stwalley Brian, Kalinsky Kevin
Аннотация
BACKGROUND: Various factors such as race/ethnicity, practice settings, socioeconomic status (SES), and geographic region influence cancer outcomes. We describe treatment patterns and outcomes among women with hormone receptor-positive/human epidermal growth factor receptor 2-negative (HR+/HER2-) metastatic breast cancer treated in the United States based on these factors.
METHODS: A retrospective, observational cohort study was conducted using the Flatiron Health Research Database of deidentified electronic health records in women ≥18 years in the United States who received first-line treatment for HR+/HER2- metastatic breast cancer from January 1, 2015, to February 28, 2023. Real-world overall survival (rwOS) and time to next treatment or death (rwTTNTD) were assessed using Kaplan-Meier methods.
RESULTS: The analysis included 6,974 women, who were most commonly non-Hispanic White (64%), lived in the South (37%), and received treatment in community settings (83%). From 2015 to 2019, the early uptake period of cyclin-dependent kinase 4/6 inhibitors (CDK4/6i), non-Hispanic White women were more likely to receive endocrine therapy (ET) + CDK4/6i compared with non-Hispanic Black and Hispanic/Latino women; ET + CDK4/6i was less common in lower (Q1-Q3) versus higher (Q4-Q5) SES quintiles and in community versus academic settings. These differences were less pronounced from 2020 to 2023. Non-Hispanic White women had significantly longer rwOS compared with non-Hispanic Black women but shorter rwOS compared with Hispanic/Latino women. rwOS was longer in academic versus community settings. No substantial differences in rwTTNTD were observed.
CONCLUSIONS: We observed disparities in first-line treatment and outcomes among women with HR+/HER2- metastatic breast cancer during a time of changes to the standard of care across racial/ethnic groups and practice settings.
IMPACT: These findings emphasize the need for improved access to evidence-based therapies, particularly in underrepresented populations.
METHODS: A retrospective, observational cohort study was conducted using the Flatiron Health Research Database of deidentified electronic health records in women ≥18 years in the United States who received first-line treatment for HR+/HER2- metastatic breast cancer from January 1, 2015, to February 28, 2023. Real-world overall survival (rwOS) and time to next treatment or death (rwTTNTD) were assessed using Kaplan-Meier methods.
RESULTS: The analysis included 6,974 women, who were most commonly non-Hispanic White (64%), lived in the South (37%), and received treatment in community settings (83%). From 2015 to 2019, the early uptake period of cyclin-dependent kinase 4/6 inhibitors (CDK4/6i), non-Hispanic White women were more likely to receive endocrine therapy (ET) + CDK4/6i compared with non-Hispanic Black and Hispanic/Latino women; ET + CDK4/6i was less common in lower (Q1-Q3) versus higher (Q4-Q5) SES quintiles and in community versus academic settings. These differences were less pronounced from 2020 to 2023. Non-Hispanic White women had significantly longer rwOS compared with non-Hispanic Black women but shorter rwOS compared with Hispanic/Latino women. rwOS was longer in academic versus community settings. No substantial differences in rwTTNTD were observed.
CONCLUSIONS: We observed disparities in first-line treatment and outcomes among women with HR+/HER2- metastatic breast cancer during a time of changes to the standard of care across racial/ethnic groups and practice settings.
IMPACT: These findings emphasize the need for improved access to evidence-based therapies, particularly in underrepresented populations.